Unnur Gudnadottir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Unnur Gudnadottir has a total of 89 co-authors. Here are the top co-authors by number of shared publications:
- Nele Brusselaers
Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden
11 shared publications Emma Fransson
Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Solna, Sweden
5 shared publicationsLars Engstrand
Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Solna, Sweden
5 shared publicationsNele Brusselaers
Department of Women's and Children's Health, Karolinska Institutet, Solna, 171 77, Sweden
5 shared publicationsJuan Du
Centre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Solna, Sweden
4 shared publications- Emma Fransson
Department of Women's and Children's Health, Uppsala University, 751 85 Uppsala, Sweden; Institute of Environmental Medicine, Karolinska Institutet, 17177 Stockholm, Sweden
3 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Oxford University Press (OUP) in Human Reproduction Update
Vaginal microbiome composition and medically assisted reproduction outcomes: a systematic review and network meta-analysis of 2289 women across three WHO regions
BACKGROUND: The vaginal microbiome may influence the success of medically assisted reproduction (MAR), including IVF with or without ICSI, and IUI. However, findings across studies remain inconsistent, and previous meta-analyses have largely relied on binary microbiome classifications or pairwise comparisons. The relative associations between individual vaginal community state types (CSTs) and pregnancy outcomes therefore remain uncertain. OBJECTIVE AND RATIONALE: To compare the associations between individual CSTs and pregnancy following MAR by integrating direct and indirect evidence in a systematic review and network meta-analysis (NMA) and to determine whether specific CSTs were associated with lower odds of pregnancy. SEARCH METHODS: PubMed, Embase, Web of Science, and the Cochrane Library were searched from database inception to 2 April 2026. Eligible longitudinal studies assessed vaginal microbiome composition using sequencing-based profiling before embryo transfer or IUI and reported pregnancy following MAR. Cross-sectional studies, studies without CST classification, or pregnancy outcome data, and studies based solely on post-treatment sampling were excluded. Two reviewers independently performed study selection and risk-of-bias assessment. Odds ratios (ORs) with 95% CIs were synthesized across CSTs using NMA. Twelve longitudinal studies including 2289 women met the inclusion criteria. The prospectively registered review was reported in accordance with PRISMA and the PRISMA extension for NMA. OUTCOMES: The NMA allowed integration of direct and indirect evidence across six CST categories. Compared with Lactobacillus (L.) crispatus, Lactobacillus jensenii-dominated CSTs (OR 0.42, 95% CI 0.19–0.92), and low-lactobacillus community CSTs (OR 0.59, 95% CI 0.38–0.91) were associated with significantly lower odds of pregnancy. No statistically significant differences were observed for other lactobacilli, including Lactobacillus gasseri and Lactobacillus iners, compared with L. crispatus. Tests found no evidence of overall or loop inconsistency in the primary network. Subgroup analyses showed broadly similar patterns but were limited by sparse data, imprecision, and local inconsistency in some subgroup networks. Interpretation was further limited by clinical and methodological heterogeneity, observational study designs, residual confounding, and sparse evidence for several CST comparisons. Live-birth evidence was particularly limited: only five studies reported a total of 57 live births. Transitivity could not be formally assessed because potential effect modifiers were not consistently reported for individual CSTs. WIDER IMPLICATIONS: The findings indicate that general assumption of Lactobacillus-dominated CSTs being beneficial to MAR-treatment effects should be regarded with caution, as these may differ in their associations with pregnancy, depending on the specific Lactobacillus dominance. However, the available evidence is insufficient to support clinical implementation of CST profiling. Larger, standardized prospective longitudinal studies with CST-specific reporting, adjusted estimates, repeated microbiome sampling, and live-birth outcomes are required to determine whether CST profiling has clinically useful prognostic value and whether microbiome-targeted interventions improve reproductive outcomes. REGISTRATION NUMBER: PROSPERO CRD420251066092.
- 15 October 2026
- Published by Oxford University Press (OUP) in Human Reproduction Update
Open AccessVaginal microbiome composition and medically assisted reproduction outcomes: a systematic review and network meta-analysis of 2289 women across three WHO regions
BACKGROUND: The vaginal microbiome may influence the success of medically assisted reproduction (MAR), including IVF with or without ICSI, and IUI. However, findings across studies remain inconsistent, and previous meta-analyses have largely relied on binary microbiome classifications or pairwise comparisons. The relative associations between individual vaginal community state types (CSTs) and pregnancy outcomes therefore remain uncertain. OBJECTIVE AND RATIONALE: To compare the associations between individual CSTs and pregnancy following MAR by integrating direct and indirect evidence in a systematic review and network meta-analysis (NMA) and to determine whether specific CSTs were associated with lower odds of pregnancy. SEARCH METHODS: PubMed, Embase, Web of Science, and the Cochrane Library were searched from database inception to 2 April 2026. Eligible longitudinal studies assessed vaginal microbiome composition using sequencing-based profiling before embryo transfer or IUI and reported pregnancy following MAR. Cross-sectional studies, studies without CST classification, or pregnancy outcome data, and studies based solely on post-treatment sampling were excluded. Two reviewers independently performed study selection and risk-of-bias assessment. Odds ratios (ORs) with 95% CIs were synthesized across CSTs using NMA. Twelve longitudinal studies including 2289 women met the inclusion criteria. The prospectively registered review was reported in accordance with PRISMA and the PRISMA extension for NMA. OUTCOMES: The NMA allowed integration of direct and indirect evidence across six CST categories. Compared with Lactobacillus (L.) crispatus, Lactobacillus jensenii-dominated CSTs (OR 0.42, 95% CI 0.19–0.92), and low-lactobacillus community CSTs (OR 0.59, 95% CI 0.38–0.91) were associated with significantly lower odds of pregnancy. No statistically significant differences were observed for other lactobacilli, including Lactobacillus gasseri and Lactobacillus iners, compared with L. crispatus. Tests found no evidence of overall or loop inconsistency in the primary network. Subgroup analyses showed broadly similar patterns but were limited by sparse data, imprecision, and local inconsistency in some subgroup networks. Interpretation was further limited by clinical and methodological heterogeneity, observational study designs, residual confounding, and sparse evidence for several CST comparisons. Live-birth evidence was particularly limited: only five studies reported a total of 57 live births. Transitivity could not be formally assessed because potential effect modifiers were not consistently reported for individual CSTs. WIDER IMPLICATIONS: The findings indicate that general assumption of Lactobacillus-dominated CSTs being beneficial to MAR-treatment effects should be regarded with caution, as these may differ in their associations with pregnancy, depending on the specific Lactobacillus dominance. However, the available evidence is insufficient to support clinical implementation of CST profiling. Larger, standardized prospective longitudinal studies with CST-specific reporting, adjusted estimates, repeated microbiome sampling, and live-birth outcomes are required to determine whether CST profiling has clinically useful prognostic value and whether microbiome-targeted interventions improve reproductive outcomes. REGISTRATION NUMBER: PROSPERO CRD420251066092.
- Open Access
- 3 September 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (5)
Swedish matched cohort on the association between maternal polyendocrine metabolic ovarian syndrome and next-generation cancer risk
Background: Polyendocrine metabolic ovarian syndrome (PMOS) is an endocrine and metabolic disorder associated with adverse perinatal and long-term health outcomes, yet its impact on cancer risk in children remains unclear. Methods: We conducted a nationwide, register-based matched cohort study in Sweden, including children of primiparous women with (N = 22 955) and without PMOS (N = 103 613) born between 1973 and 2018. Children were followed from birth until cancer diagnosis, death, or December 2018. Conditional Cox proportional hazards models estimated the adjusted hazard ratio (aHR) with 95% CI, incorporating time-varying effects when the proportional hazards assumption was violated. Results: During follow-up, 666 children were diagnosed with cancer. Compared with children born to women without PMOS, overall cancer risk among children of women with PMOS differed by sex and over time. Among sons, higher hazards at 1 year were observed (aHR = 4.17; 95% CI = 2.51 to 6.93), decreasing by 10 years (aHR = 1.53; 95% CI = 1.08 to 2.18). In daughters, hazard ratios did not indicate a change in overall cancer risk compared to reference. When both sexes were combined, risk of lymphatic and hematopoietic malignancies was higher (aHR = 2.43; 95% CI = 1.36 to 4.33). Competing risks of death did not materially alter the associations. Conclusions: Overall cancer risk among children born to women with PMOS differed by sex and over time, with higher risks in sons during early life. These findings suggest that maternal PMOS may be associated with differential cancer susceptibility across the life course.
- 3 September 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (5)
Open AccessSwedish matched cohort on the association between maternal polyendocrine metabolic ovarian syndrome and next-generation cancer risk
Background: Polyendocrine metabolic ovarian syndrome (PMOS) is an endocrine and metabolic disorder associated with adverse perinatal and long-term health outcomes, yet its impact on cancer risk in children remains unclear. Methods: We conducted a nationwide, register-based matched cohort study in Sweden, including children of primiparous women with (N = 22 955) and without PMOS (N = 103 613) born between 1973 and 2018. Children were followed from birth until cancer diagnosis, death, or December 2018. Conditional Cox proportional hazards models estimated the adjusted hazard ratio (aHR) with 95% CI, incorporating time-varying effects when the proportional hazards assumption was violated. Results: During follow-up, 666 children were diagnosed with cancer. Compared with children born to women without PMOS, overall cancer risk among children of women with PMOS differed by sex and over time. Among sons, higher hazards at 1 year were observed (aHR = 4.17; 95% CI = 2.51 to 6.93), decreasing by 10 years (aHR = 1.53; 95% CI = 1.08 to 2.18). In daughters, hazard ratios did not indicate a change in overall cancer risk compared to reference. When both sexes were combined, risk of lymphatic and hematopoietic malignancies was higher (aHR = 2.43; 95% CI = 1.36 to 4.33). Competing risks of death did not materially alter the associations. Conclusions: Overall cancer risk among children born to women with PMOS differed by sex and over time, with higher risks in sons during early life. These findings suggest that maternal PMOS may be associated with differential cancer susceptibility across the life course.
- Open Access
- 11 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Group B Streptococcus antibiotics treatment during pregnancy and the risk of four neurodevelopmental outcomes in Swedish children
Recent studies have suggested an association between prenatal and early life antibiotics with adverse neurodevelopmental outcomes in children. As antibiotics during pregnancy are commonly prescribed, our aim was to estimate the association the groups of antibiotics prescribed for GBS during pregnancy the risk of neurodevelopmental outcomes in children. This population-based cohort study included all live births in Sweden from 2006 to 2016 ( n = 1,066,777). Individual informed consent was not required, as the study used data from national registers and involved no direct participant contact. Using multivariable Cox Regression models and GEE models for secondary assessment we measured the association between seven first line treatment GBS antibiotics during pregnancy and (1) intellectual disability, (2) cerebral palsy, (3) autism spectrum disorder (ASD), and (4) attention deficit hyperactivity disorder (ADD/ADHD) as recorded in high-quality Swedish registers. GBS antibiotics were prescribed to 22.1% of mothers included. We found no association between GBS antibiotics and the risk of intellectual disability. However, a modest association was observed for cerebral palsy (aHR 1.17, 95%CI 1.06–1.29), ASD (aHR 1.12, 95%CI 1.07–1.17), and ADHD/ADD (aHR 1.17, 95%CI 1.12–1.22). This association was also seen when only including children born at term, and only children of mothers without autism spectrum disorder or ADHD diagnosis. The results were model dependent, as GEE models did not always show the same associations. Although the results could be affected by residual confounding or confounding by indication (as GBS infection has been associated with neurodevelopmental outcomes), they highlight the need for further studies on GBS antibiotic use during pregnancy, increased antibiotic stewardship with individual risk assessment and other treatment options for GBS, when needed.
- 11 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessGroup B Streptococcus antibiotics treatment during pregnancy and the risk of four neurodevelopmental outcomes in Swedish children
Recent studies have suggested an association between prenatal and early life antibiotics with adverse neurodevelopmental outcomes in children. As antibiotics during pregnancy are commonly prescribed, our aim was to estimate the association the groups of antibiotics prescribed for GBS during pregnancy the risk of neurodevelopmental outcomes in children. This population-based cohort study included all live births in Sweden from 2006 to 2016 ( n = 1,066,777). Individual informed consent was not required, as the study used data from national registers and involved no direct participant contact. Using multivariable Cox Regression models and GEE models for secondary assessment we measured the association between seven first line treatment GBS antibiotics during pregnancy and (1) intellectual disability, (2) cerebral palsy, (3) autism spectrum disorder (ASD), and (4) attention deficit hyperactivity disorder (ADD/ADHD) as recorded in high-quality Swedish registers. GBS antibiotics were prescribed to 22.1% of mothers included. We found no association between GBS antibiotics and the risk of intellectual disability. However, a modest association was observed for cerebral palsy (aHR 1.17, 95%CI 1.06–1.29), ASD (aHR 1.12, 95%CI 1.07–1.17), and ADHD/ADD (aHR 1.17, 95%CI 1.12–1.22). This association was also seen when only including children born at term, and only children of mothers without autism spectrum disorder or ADHD diagnosis. The results were model dependent, as GEE models did not always show the same associations. Although the results could be affected by residual confounding or confounding by indication (as GBS infection has been associated with neurodevelopmental outcomes), they highlight the need for further studies on GBS antibiotic use during pregnancy, increased antibiotic stewardship with individual risk assessment and other treatment options for GBS, when needed.
- Open Access
- 13 March 2026
- Published by Springer Nature in npj Biofilms and Microbiomes
- Vol. 12 (1)
Machine learning and the role of the vaginal and fecal microbiome in miscarriage: a matched case-control study
Miscarriage occurs in approximately 15% of all pregnancies, and recent studies have suggested a potential role of the microbiome. A nested case-control study from the Swedish Maternal Microbiome cohort was conducted, including 34 participants who sent at least one vaginal or fecal microbiome sample and questionnaire data before miscarrying ( n = 34), and matched controls ( n = 105 for regression models, n = 27 for machine learning models). Non-vaccine type HPV (aOR 3.95, 95%CI 1.04–15.06) and vaginal microbiome with community state type (CST) II (aOR 6.52, 95%CI 1.58–26.98) or CST-IVB (aOR 4.18, 95%CI 1.08–16.18) in early pregnancy were associated with an increased risk of miscarriage. Furthermore, we explored six machine learning algorithms using 70% of the cohort for training and 30% for testing, for the prediction of miscarriage using vaginal (AUROC 85%), fecal (AUROC 81%) and questionnaire (AUROC 82%) data separately and combined (AUROC 82%). Our results highlight the urgency of HPV screening and vaccine development for women’s reproductive health. Despite limitations, including a small number of miscarriage cases, our results indicate the potential for both vaginal and fecal microbiomes in the prediction of miscarriage.
- 13 March 2026
- Published by Springer Nature in npj Biofilms and Microbiomes
- Vol. 12 (1)
Open AccessMachine learning and the role of the vaginal and fecal microbiome in miscarriage: a matched case-control study
Miscarriage occurs in approximately 15% of all pregnancies, and recent studies have suggested a potential role of the microbiome. A nested case-control study from the Swedish Maternal Microbiome cohort was conducted, including 34 participants who sent at least one vaginal or fecal microbiome sample and questionnaire data before miscarrying ( n = 34), and matched controls ( n = 105 for regression models, n = 27 for machine learning models). Non-vaccine type HPV (aOR 3.95, 95%CI 1.04–15.06) and vaginal microbiome with community state type (CST) II (aOR 6.52, 95%CI 1.58–26.98) or CST-IVB (aOR 4.18, 95%CI 1.08–16.18) in early pregnancy were associated with an increased risk of miscarriage. Furthermore, we explored six machine learning algorithms using 70% of the cohort for training and 30% for testing, for the prediction of miscarriage using vaginal (AUROC 85%), fecal (AUROC 81%) and questionnaire (AUROC 82%) data separately and combined (AUROC 82%). Our results highlight the urgency of HPV screening and vaccine development for women’s reproductive health. Despite limitations, including a small number of miscarriage cases, our results indicate the potential for both vaginal and fecal microbiomes in the prediction of miscarriage.
- Open Access
- 29 December 2025
- Published by Elsevier in Journal of Infection
- Vol. 92 (2) , 106669
Antibiotic use during pregnancy and neonatal Group B Streptococcus disease
- 29 December 2025
- Published by Elsevier in Journal of Infection
- Vol. 92 (2) , 106669
Open AccessAntibiotic use during pregnancy and neonatal Group B Streptococcus disease
- Open Access
- 22 December 2025
- Published by Taylor & Francis in Gut Microbes Reports
- Vol. 3 (1) , 2603861
The gut microbiome in early pregnancy is associated with the severity of nausea and vomiting: a nested case‒control study
Nausea and vomiting of pregnancy (NVP) are experienced by roughly 70% of pregnant individuals.1 Symptoms of nausea and/or vomiting can start as early as gestational week 4 and usually peak at week ...
- 22 December 2025
- Published by Taylor & Francis in Gut Microbes Reports
- Vol. 3 (1) , 2603861
Open AccessThe gut microbiome in early pregnancy is associated with the severity of nausea and vomiting: a nested case‒control study
Nausea and vomiting of pregnancy (NVP) are experienced by roughly 70% of pregnant individuals.1 Symptoms of nausea and/or vomiting can start as early as gestational week 4 and usually peak at week ...
- Open Access
Metabolic differences in the maternal gut microbiome precede the birth of large-for-gestational-age infants: A nested case-control study
Background: Neonatal size influences newborn health and is affected by prenatal factors, such as the maternal gut microbiome, which impacts maternal metabolism and fetal growth. Methods: A nested case-control study (1:2 matched) was conducted within the Swedish Maternal Microbiome (SweMaMi, 2017–2021) cohort to investigate the associations between maternal gut microbiome profiles during pregnancy and the risk of delivering large-for-gestational-age (LGA; birth weight >90th percentile) infants compared to appropriate-for-gestational-age (AGA; birth weight 10-90th percentile) infants, with a focus on dietary influence. Shotgun metagenomics enabled taxonomic and functional profiling of fecal samples collected during early (TP1: 10–20 weeks; n = 245:490) and late pregnancy (TP2: 28–32 weeks; n = 157:314). Additionally, we analyzed within-group changes in microbiome diversity from TP1 to TP2 to compare longitudinal patterns between the groups. Results: At TP1, microbial species richness was higher in mothers of LGA infants (p = 0.01, 95% CI: 3.26 to 24.9), but this difference was not observed at TP2 (p = 0.30, 95% CI: –7.04 to 22.7). Beta diversity (overall microbial structure) did not differ significantly between groups at either time point. Within-sample diversity, as measured by the Shannon index, showed a significantly greater decline in the LGA group compared to the AGA group (p = 0.03, 95% CI: –0.13 to –0.007), suggesting a loss of microbial diversity specific to the LGA group over time. Evenness also declined in both groups, but the change was significantly more pronounced in the LGA group (p = 0.047, 95% CI: –0.02 to –0.0001. At TP1, the LGA group was functionally enriched in proteolytic pathways, while the AGA, group was associated with short-chain fatty acid (SCFA) production, a connection that remained at TP2. In contrast, the LGA group displayed a shift toward a pathway involved in glucose production. Limitations: Reliance on self-reported dietary data, lack of physical activity and pre-pregnancy diet information, and a highly educated study population may limit generalizability. Conclusion: Early pregnancy gut microbiome diversity and function, along with maternal factors, may contribute to the risk of fetal overgrowth. While microbiome diversity converges between cases and controls at a later time-point, this is not enough to mitigate risk.
Open AccessMetabolic differences in the maternal gut microbiome precede the birth of large-for-gestational-age infants: A nested case-control study
Background: Neonatal size influences newborn health and is affected by prenatal factors, such as the maternal gut microbiome, which impacts maternal metabolism and fetal growth. Methods: A nested case-control study (1:2 matched) was conducted within the Swedish Maternal Microbiome (SweMaMi, 2017–2021) cohort to investigate the associations between maternal gut microbiome profiles during pregnancy and the risk of delivering large-for-gestational-age (LGA; birth weight >90th percentile) infants compared to appropriate-for-gestational-age (AGA; birth weight 10-90th percentile) infants, with a focus on dietary influence. Shotgun metagenomics enabled taxonomic and functional profiling of fecal samples collected during early (TP1: 10–20 weeks; n = 245:490) and late pregnancy (TP2: 28–32 weeks; n = 157:314). Additionally, we analyzed within-group changes in microbiome diversity from TP1 to TP2 to compare longitudinal patterns between the groups. Results: At TP1, microbial species richness was higher in mothers of LGA infants (p = 0.01, 95% CI: 3.26 to 24.9), but this difference was not observed at TP2 (p = 0.30, 95% CI: –7.04 to 22.7). Beta diversity (overall microbial structure) did not differ significantly between groups at either time point. Within-sample diversity, as measured by the Shannon index, showed a significantly greater decline in the LGA group compared to the AGA group (p = 0.03, 95% CI: –0.13 to –0.007), suggesting a loss of microbial diversity specific to the LGA group over time. Evenness also declined in both groups, but the change was significantly more pronounced in the LGA group (p = 0.047, 95% CI: –0.02 to –0.0001. At TP1, the LGA group was functionally enriched in proteolytic pathways, while the AGA, group was associated with short-chain fatty acid (SCFA) production, a connection that remained at TP2. In contrast, the LGA group displayed a shift toward a pathway involved in glucose production. Limitations: Reliance on self-reported dietary data, lack of physical activity and pre-pregnancy diet information, and a highly educated study population may limit generalizability. Conclusion: Early pregnancy gut microbiome diversity and function, along with maternal factors, may contribute to the risk of fetal overgrowth. While microbiome diversity converges between cases and controls at a later time-point, this is not enough to mitigate risk.
- Open Access
- 15 April 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (1) , 206-217
Prenatal and Early Childhood Exposure to Antibiotics or Gastric Acid Inhibitors and Increased Risk of Epilepsy: A Nationwide Population‐Based Study
Over 10 million children in the world have epilepsy, with an unknown cause in half of the cases. The gut microbiome has been associated with various neurological disorders, and certain drugs greatly disturb the microbiome. Our aim was to study the association of prenatal and childhood exposure (before the age of two) to antibiotics, proton pump inhibitors (PPIs) and histamine‐2 receptor antagonists, and the risk of childhood epilepsy. Using population‐based registers, we included all live singleton births in Sweden from 2006 to 2017. Exposure was considered prescription(s) to antibiotics, proton pump inhibitors, or H2‐receptor antagonists (separately). Multivariable Cox regression was used to calculate hazard ratios and 95% confidence intervals. 708,903 mother–child dyads were included, and 0.5% of children had an epilepsy diagnosis. Average follow‐up was 3.8 years (IQR 1–6). Prenatal exposure to antibiotics (aHR 1.09, 95% CI 1.01–1.18) and PPIs (aHR 1.38, 95% CI 1.17–1.65) were associated with an increased risk of epilepsy. Exposure to antibiotics (1.11, 95% CI 1.02–1.21), PPIs (3.40, 95% CI 2.47–4.68) and H2RAs (1.65, 95% CI 1.03–2.64) before the age of two was associated with an increased risk of epilepsy after the age of two. Dose response analysis showed that one prescription of antibiotics in pregnancy or early life was not associated with an increased risk of epilepsy, while one prescription of PPIs in pregnancy or early life had an association. To conclude, our results support the hypothesis that microbiome modulating drugs are associated with an increased risk of epilepsy. This needs to be further validated in other studies, ideally including indications for drug use.
- 15 April 2025
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 118 (1) , 206-217
Open AccessPrenatal and Early Childhood Exposure to Antibiotics or Gastric Acid Inhibitors and Increased Risk of Epilepsy: A Nationwide Population‐Based Study
Over 10 million children in the world have epilepsy, with an unknown cause in half of the cases. The gut microbiome has been associated with various neurological disorders, and certain drugs greatly disturb the microbiome. Our aim was to study the association of prenatal and childhood exposure (before the age of two) to antibiotics, proton pump inhibitors (PPIs) and histamine‐2 receptor antagonists, and the risk of childhood epilepsy. Using population‐based registers, we included all live singleton births in Sweden from 2006 to 2017. Exposure was considered prescription(s) to antibiotics, proton pump inhibitors, or H2‐receptor antagonists (separately). Multivariable Cox regression was used to calculate hazard ratios and 95% confidence intervals. 708,903 mother–child dyads were included, and 0.5% of children had an epilepsy diagnosis. Average follow‐up was 3.8 years (IQR 1–6). Prenatal exposure to antibiotics (aHR 1.09, 95% CI 1.01–1.18) and PPIs (aHR 1.38, 95% CI 1.17–1.65) were associated with an increased risk of epilepsy. Exposure to antibiotics (1.11, 95% CI 1.02–1.21), PPIs (3.40, 95% CI 2.47–4.68) and H2RAs (1.65, 95% CI 1.03–2.64) before the age of two was associated with an increased risk of epilepsy after the age of two. Dose response analysis showed that one prescription of antibiotics in pregnancy or early life was not associated with an increased risk of epilepsy, while one prescription of PPIs in pregnancy or early life had an association. To conclude, our results support the hypothesis that microbiome modulating drugs are associated with an increased risk of epilepsy. This needs to be further validated in other studies, ideally including indications for drug use.
- Open Access
Prenatal and early childhood exposure to antibiotics or gastric acid inhibitors and increased risk of epilepsy: A nationwide population-based study
Over 10 million children in the world have epilepsy, with unknown root cause in approximately half of cases. The gut microbiome has been associated with various neurological disorders, and certain drugs greatly disturb the microbiome. Our aim was to study the association of prenatal and childhood exposure (before the age of two) of antibiotics, proton pump inhibitors and histamine-2 receptor antagonists, and the risk of childhood epilepsy. Using population-based registers, we included all live singleton births in Sweden from 2006-2017. Exposure was considered prescription(s) to antibiotics, proton pump inhibitors or H2-receptor antagonists (separately) during pregnancy or the first two years of life. Multivariable Cox regression was used to calculate hazard ratios and 95% confidence intervals. In total 708,903 mother-child dyads were included, and 0.5% of children were diagnosed with epilepsy. Average follow-up time was 3.8 years (IQR 1-6). Prenatal exposure to antibiotics (aHR 1.09, 95%CI 1.01-1.18) and proton pump inhibitors (aHR 1.38, 95%CI 1.17-1.65) were associated with an increased risk of epilepsy. Additionally, exposure to antibiotics (1.13, 95%CI 1.04-1.23), PPIs (3.82, 95%CI 2.83-5.16) and H2RAs (1.65, 95%CI 1.03-2.64) before the age of two was associated with an increased risk of epilepsy after the age of two. To conclude, our results support the hypothesis that microbiome modulating drugs are associated with an increased risk of epilepsy. This association needs to be further validated in other studies, ideally including the indications for drug use. Our results hopefully contribute to further studies or better prevention of childhood epilepsy.
Open AccessPrenatal and early childhood exposure to antibiotics or gastric acid inhibitors and increased risk of epilepsy: A nationwide population-based study
Over 10 million children in the world have epilepsy, with unknown root cause in approximately half of cases. The gut microbiome has been associated with various neurological disorders, and certain drugs greatly disturb the microbiome. Our aim was to study the association of prenatal and childhood exposure (before the age of two) of antibiotics, proton pump inhibitors and histamine-2 receptor antagonists, and the risk of childhood epilepsy. Using population-based registers, we included all live singleton births in Sweden from 2006-2017. Exposure was considered prescription(s) to antibiotics, proton pump inhibitors or H2-receptor antagonists (separately) during pregnancy or the first two years of life. Multivariable Cox regression was used to calculate hazard ratios and 95% confidence intervals. In total 708,903 mother-child dyads were included, and 0.5% of children were diagnosed with epilepsy. Average follow-up time was 3.8 years (IQR 1-6). Prenatal exposure to antibiotics (aHR 1.09, 95%CI 1.01-1.18) and proton pump inhibitors (aHR 1.38, 95%CI 1.17-1.65) were associated with an increased risk of epilepsy. Additionally, exposure to antibiotics (1.13, 95%CI 1.04-1.23), PPIs (3.82, 95%CI 2.83-5.16) and H2RAs (1.65, 95%CI 1.03-2.64) before the age of two was associated with an increased risk of epilepsy after the age of two. To conclude, our results support the hypothesis that microbiome modulating drugs are associated with an increased risk of epilepsy. This association needs to be further validated in other studies, ideally including the indications for drug use. Our results hopefully contribute to further studies or better prevention of childhood epilepsy.
- Open Access
- 12 December 2024
- Published by Springer Nature in Drug Safety
- Vol. 48 (4) , 375-388
Prenatal and Early Childhood Exposure to Proton Pump Inhibitors and Antibiotics and the Risk of Childhood Cancer: A Nationwide Population-Based Cohort Study
Background Our microbiome is established during infancy, a time important for later health and long-term effects. Proton pump inhibitors and antibiotics are regularly prescribed during pregnancy. Both drugs cause microbiome disturbance and have been associated with increased cancer risk in adults, but effects of these drugs on the growing foetus and infant remain understudied. Aim The aim of this study is to study the association between prenatal and early life proton pump inhibitor and antibiotics exposure and the risk of childhood cancer. Methods This study is a retrospective population-based cohort design, using registry data on all births (n = 722,372) in Sweden between 2006 and 2016, according to the STROBE checklist. For women who had multiple children in the timeframe of the study, only the first child during the time period was included in the cohort. Exposure was defined as either ≥ 1 proton pump inhibitor or antibiotics prescription during pregnancy, or during the first 2 years of life. Outcome was defined as cancer at any time during the follow-up or cancer after the age of 2 years for early life exposure. Multivariable Cox proportional hazard models were used to calculate hazard ratios. Results In total, 1091 (0.2%) children were diagnosed with malignant cancer during the follow-up. Prenatal exposure to proton pump inhibitors and antibiotics were not associated with an increased risk of cancer. Regarding early life exposure, proton pump inhibitors were associated with an increased risk of cancer at age two or older (adjusted hazard ratio [aHR] 3.68, 95% confidence interval [CI] 2.24–6.06). Conclusions We did not find evidence that prenatal proton pump inhibitors and antibiotics were associated with overall childhood cancer. However, proton pump inhibitors during early life were associated with an increased risk of childhood cancer, but indication on drug use was not available and confounding by indication may be present. Graphical Abstract
- 12 December 2024
- Published by Springer Nature in Drug Safety
- Vol. 48 (4) , 375-388
Open AccessPrenatal and Early Childhood Exposure to Proton Pump Inhibitors and Antibiotics and the Risk of Childhood Cancer: A Nationwide Population-Based Cohort Study
Background Our microbiome is established during infancy, a time important for later health and long-term effects. Proton pump inhibitors and antibiotics are regularly prescribed during pregnancy. Both drugs cause microbiome disturbance and have been associated with increased cancer risk in adults, but effects of these drugs on the growing foetus and infant remain understudied. Aim The aim of this study is to study the association between prenatal and early life proton pump inhibitor and antibiotics exposure and the risk of childhood cancer. Methods This study is a retrospective population-based cohort design, using registry data on all births (n = 722,372) in Sweden between 2006 and 2016, according to the STROBE checklist. For women who had multiple children in the timeframe of the study, only the first child during the time period was included in the cohort. Exposure was defined as either ≥ 1 proton pump inhibitor or antibiotics prescription during pregnancy, or during the first 2 years of life. Outcome was defined as cancer at any time during the follow-up or cancer after the age of 2 years for early life exposure. Multivariable Cox proportional hazard models were used to calculate hazard ratios. Results In total, 1091 (0.2%) children were diagnosed with malignant cancer during the follow-up. Prenatal exposure to proton pump inhibitors and antibiotics were not associated with an increased risk of cancer. Regarding early life exposure, proton pump inhibitors were associated with an increased risk of cancer at age two or older (adjusted hazard ratio [aHR] 3.68, 95% confidence interval [CI] 2.24–6.06). Conclusions We did not find evidence that prenatal proton pump inhibitors and antibiotics were associated with overall childhood cancer. However, proton pump inhibitors during early life were associated with an increased risk of childhood cancer, but indication on drug use was not available and confounding by indication may be present. Graphical Abstract